Salmon calcitonin: A review of current and future therapeutic indications

172Citations
Citations of this article
136Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Salmon calcitonin, available as a therapeutic agent for more than 30 years, demonstrates clinical utility in the treatment of such metabolic bone diseases as osteoporosis and Paget's disease, and potentially in the treatment of osteoarthritis. This review considers the physiology and pharmacology of salmon calcitonin, the evidence based research demonstrating efficacy and safety of this medication in postmenopausal osteoporosis with potentially an effect on bone quality to explain its abilities to reduce the risk of spine fracture, the development of an oral salmon calcitonin preparation, and the therapeutic rationale for this preparation's chondroprotective effect in osteoarthritis. © International Osteoporosis Foundation and National Osteoporosis Foundation 2007.

Cite

CITATION STYLE

APA

Chesnut, C. H., Azria, M., Silverman, S., Engelhardt, M., Olson, M., & Mindeholm, L. (2008, April). Salmon calcitonin: A review of current and future therapeutic indications. Osteoporosis International. https://doi.org/10.1007/s00198-007-0490-1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free